Related Experiment Video
Updated: May 29, 2026
06:57
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites
Angamuthu Selvapandiyan1, Ranadhir Dey, Sreenivas Gannavaram
1Institute of Molecular Medicine, 254 Okhla Industrial Estate, Phase III, New Delhi 110020, India.
Journal of Tropical Medicine
|September 14, 2011
Summary
Developing live-attenuated Leishmania parasites offers a promising strategy for a visceral leishmaniasis (VL) vaccine. These genetically altered parasites aim to induce the immunological memory seen after natural infection, overcoming current treatment limitations.
Area of Science:
- Parasitology
- Vaccinology
- Infectious Diseases
Background:
- Leishmaniasis, a protozoan parasitic disease, presents in cutaneous (CL), mucocutaneous (MCL), and visceral (VL) forms.
- Current treatments for leishmaniasis are costly and face challenges with drug resistance.
- Existing subunit vaccines show limited efficacy in humans, unlike natural infection-induced immunity.
Purpose of the Study:
- To explore the development and characteristics of genetically altered, live-attenuated Leishmania donovani parasites.
- To evaluate these modified parasites as potential vaccine candidates against visceral leishmaniasis (VL).
- To discuss the challenges and considerations associated with using live-attenuated parasite vaccines.
Main Methods:
- Genetic alteration of Leishmania donovani parasites to create live-attenuated strains.
- Characterization of the developed attenuated parasites.
- Evaluation of their potential as vaccine candidates for visceral leishmaniasis.
Main Results:
- Genetically altered, live-attenuated Leishmania donovani parasites were developed.
- These attenuated parasites show potential as vaccine candidates against visceral leishmaniasis (VL).
- The study highlights the feasibility of using attenuated parasites to mimic natural immunity.
Conclusions:
- Live-attenuated Leishmania parasites represent a viable strategy for developing a visceral leishmaniasis (VL) vaccine.
- Mimicking natural infection-induced immunological memory is key to effective leishmaniasis vaccination.
- Further research is needed to address challenges in the clinical application of live-attenuated parasite vaccines.
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...